Press release
AMGEN TO PRESENT NEW REPATHA® (EVOLOCUMAB) AND OLPASIRAN DATA AT ACC
Combined Data From FOURIER and FOURIER-OLE Studies Show Earlier, Longer Use of Repatha Reduces Total CV Events Analysis From Phase 2 OCEAN(a)-DOSE Study Shows
About this update from Amgen Inc.
[{"type":"text","content":"Combined Data From FOURIER and FOURIER-OLE Studies Show Earlier, Longer Use of Repatha Reduces Total CV Events\nAnalysis From Phase 2 OCEAN(a)-DOSE Study Shows Olpasiran Markedly Reduced Lp(a) Concentration Irrespective of Baseline Level \nAmgen Convenes First LDL-C Action Summit to Help Improve State of Cardiovascular Disease Care in the U.S.\nTHOUSAND OAKS, Calif., March 1, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new Repatha® (evolocumab) combined data from the Phase 3 FOURIER and FOURIER Open Label Extension (OLE) studies and the Phase 2 OCEAN(a)-DOSE study of investigational olpasiran, an siRNA that reduces lipoprotein(a) [Lp(a)] by more than 90%. Additional data from Amgen's Center for Observational Research and Amgen funded investigator studies, including YELLOW-III from Mount Sinai will be presented at the American College of Cardiology's 72nd Annual Scientific Session together with World Heart Federation's World Congress of Cardiology (ACC.23/WCC) in New Orleans, LA, March 4-6, 2023.\nThe Repatha data evaluated all primary endpoint events from the patients enrolled in the parent FOURIER study (n=27,564), with a median follow up of 2.2 years, and for patients who received Repatha during FOURIER-OLE (n=6,635), for an additional 3 years of follow up. These findings showed that over the duration of follow-up, patients with atherosclerotic cardiovascular disease (ASCVD) who were already receiving statin therapy had a reduction in adverse cardiovasclar outcomes with earlier initiation of Repatha. This was shown by the reduction in total cardiovascular (CV) endpoint events (cardiovascular disease, myocardial infarction, stroke, unstable angina or coronary revascularization) in patients that had initiated Repatha in the parent study and continued Repatha in the OLE, as compared to those who were in the standard of care group in the parent study and only initiated Repatha during the OLE.\n\"Amgen is at the forefront of lipid research and we are focused on addressing some of the most significant cardiovascular disease risk factors, including unmanaged LDL-C and Lp(a),\" said David M. Reese, M.D., executive vice president of Research and Development at Amgen. \"The robust body of evidence on Repatha continues to underscore its clinical importance as a transformative therapy in lowering LDL-C to reduce CV events li...